|
Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2
Ashok Kumar Pandurangan, Suresh Kumar, Prakash Dharmalingam, Sudhandiran Ganapasam
Department of Biochemistry, University of Madras, Guindy Campus, Chennai, India
| Date of Submission | 02-Jul-2013 |
| Date of Acceptance | 28-Jul-2013 |
| Date of Web Publication | 28-May-2014 |
Correspondence Address:
Sudhandiran Ganapasam
Department of Biochemistry,University of Madras, Guindy Campus, Chennai - 600 025
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1296.133285
 Abstract | | |
Colon cancer (CRC) is a serious health problem through worldwide. Development of novel drug without side effect for this cancer was crucial. Luteolin (LUT), a bioflavonoid has many beneficial effects such as antioxidant, anti-inflammatory, anti-proliferative properties. Azoxymethane (AOM), a derivative of 1, 2-Dimethyl hydrazine (DMH) was used for the induction of CRC in Balb/C mice. CRC was induced by intraperitoneal injection of AOM to mice at the dose of 15 mg/body kg weight for 3 weeks. Mouse was treated with LUT at the dose of 1.2 mg/body kg weight orally until end of the experiment. The expression of inducible nitric oxide synthase (iNOS) and cyclooxygense (COX)-2 were analyzed by RT-PCR and immunohistochemistry. The expressions of iNOS and COX-2 were increased in the case of AOM induction. Administration of LUT effectively reduced the expressions of iNOS and COX-2. The present study revealed that, LUT suppresses both iNOS and COX-2 expressions and act as an anti-inflammatory role against CRC. Keywords: Azoxymethane, colon cancer, COX-2, iNOS, Luteolin
How to cite this article:
Pandurangan AK, Kumar S, Dharmalingam P, Ganapasam S. Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2. Phcog Mag 2014;10, Suppl S2:306-10 |
How to cite this URL:
Pandurangan AK, Kumar S, Dharmalingam P, Ganapasam S. Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2. Phcog Mag [serial online] 2014 [cited 2022 Jan 22];10, Suppl S2:306-10. Available from: http://www.phcog.com/text.asp?2014/10/38/306/133285 |
| Introduction | |  |
Colon cancer (CRC), a complex multi-step process involving progressive disruption of homeostatic mechanisms [1] controlling intestinal epithelial proliferation/inflammation, differentiation and programmed cell death, is the third most common malignant neoplasm worldwide. [2] Several epidemiological studies have indicated the influence of lifestyle factors, particularly nutritional factors, on the development of certain forms of cancers, including the colon carcinomas. [3],[4] AOM, a metabolite of DMH, has been used extensively to induce CRC in rodents. [5] AOM-induces cancer to both rat and mouse models were the main animal models used to study the effect of dietary agents. [6],[7] It is necessary to measure the ability of certain natural product or pharmaceutical agent to hinder the carcinogenesis process. [8]
Luteolin, a 3′,4′, 5, 7-tetrahydroxyflavone, is usually found in a glycosylated form in celery, green pepper, perilla leaf and seed, chamomile tea and Lonicera japonica. Luteolin possesses anti-inflammatory, anti-oxidant [9] and phytoestrogen like activities. [10] Several researchers had found that LUT possess anti-neoplastic activities against several human cancers. [11],[12],[13]
There are two isoforms of cyclooxygenase (COX), namely COX-1 and COX-2. COX-1 is constitutively expressed in a number of cell types and tissues and plays a major role in homeostasis. COXs are the rate-limiting enzymes in the conversion of arachidonic acid into prostaglandins (PGs). COX-2 catalyzes the conversion of arachidonic acid into PGH 2 and it is further converted into Prostaglandins and thromboxane A 2 by prostaglandin synthase and thromboxane synthase respectively. The formation of PGH 2 occurs in two steps; initially, two oxygen molecules are incorporated into arachidonate, thus generating PGG 2 . The synthesis of PGH 2 is the second step and it involves reduction of PGG 2 catalyzed by the peroxidase activity of COX-2. COX-2 is not detected in most normal tissues but is rapidly induced in response to mitogens, cytokines and tumor promoters, leading to increased accumulation of prostanoids in neoplastic and inflamed tissues. [14] Accumulated evidence suggests that COX-2 selective inhibitors such as non-steroidal anti-inflammatory drugs (NSAIDS) induce apoptosis by suppressing the COX-2. [15]
Varity of natural compounds have the potential to control the neoplasms. Our own observations revealed that Luteolin inhibit CRC in vivo. [16],[17],[18] Hence, our present investigation focused to study inhibitory effect of LUT against the crucial inflammatory molecules involved in CRC such as iNOS and COX-2.
| Matrials and methods | | |
Animals
Male Balb/c mice weighing approximately 25 to 30gm were obtained from the Laboratory Animal Maintenance Unit, Tamilnadu Animal Science and Veterinary University (TANUVAS), Madavaram, India. The animals were acclimatized to the laboratory conditions for a period of two weeks. They were maintained at an ambient temperature of 25 ± 2°C and 12/12h of light-dark cycle and given a standard rat feed (Hindustan Lever Ltd., Bangalore) and water ad libitum. The experiments involved with animals were conducted according to the ethical norms approved by Ministry of Social Justices and Empowerment, Government of India and Institutional Animal Ethics Committee Guidelines.
Experimental procedure
The animals were divided into four groups (n = 6 per group). Group 1 - Control animals received intra peritoneal injections (i.p.) of physiological saline. Group 2 animals were administered with AOM (15mg/kg body weight) intraperitoneally (i.p.) once in week for three weeks. Group 3 animals (AOM + LUT) were treated with a single dose with 1.2mg/kg body weight of LUT orally until end of the experiment, after AOM administration as mentioned in group 2. [9] Group 4 received the same dose of LUT alone as mentioned in group 3.
Assay of Alkaline Phosphatase and Lactate Dehydrogenase
Lactate dehydrogenase was assayed according to the method described by King (1965a). [19] Alkaline phosphatase was assayed by the method described by King (1965b). [20]
Immunohistochemical analysis of iNOS and COX-2
Immunohistochemical analysis of iNOS and COX-2 were analyzed by the method Ashokkumar and Sudhandiran, (2011). [21] The stained slides were visualized under a light microscope (Nikon XDS-1B). To measure the relative intensity, scoring was done as arbitrary units 4 as intensely stained, 3 as moderately stained, 2 as mild staining, 1 as poorly stained in control and experimental groups.
RNA Isolation and PCR analysis
Isolation of RNA and RT-PCR analysis of iNOS and COX-2 were followed by the method Ashokkumar and Sudhandiran, (2011). [21] Total cellular RNA was extracted from colon tissues using the TRIzol reagent (Bangalore Genei, Bangalore, India). cDNA was synthesized from 2μg of total RNA using M-MuLV reverse transcriptase (Bangalore Genei, India). The cDNA for iNOS, COX-2 and actin were amplified by PCR with gene specific primers [Table 1]. PCR products were analyzed in an agarose gel electrophoresis and visualized by ethidium bromide staining.
Statistical analysis
All the data were statistically evaluated with SPSS/10.0 software. Hypothesis testing methods included one-way analysis of variance followed by least significant difference (LSD) test *P < 0.05 was considered to indicate statistical significance. All the results were expressed as mean ± S.D.
| Results | | |
Luteolin reduces the levels of Alkaline phosphatase and Lactate Dehydrogenase
ALP is a non-specific phosphomonoester hydrolase that catalyses the hydrolysis of wide variety of organic monophosphatases and it is a useful marker for the determination of differentiation in colon cancer cells. LDH is recognized as a potential tumor marker enzyme in assessing the proliferation of malignant cells. The possible reason for elevated levels of LDH may be due to higher glycolysis in cancerous conditions, which is the only energy producing pathway for the uncontrolled proliferating malignant cells. [Figure 1] shows the levels of ALP and LDH in control and experimental groups of mice. Administration of AOM (Group 2) facilitates the increase in the levels of ALP and LDH. LUT (group 3) treatment substantially reduced the levels of ALP and LDH. In control (Group 1) and LUT (Group 4) state no such alteration in the levels of ALP and LDH enzyme were observed. | Figure 1: Luteolin reduced the levels of ALP and LDH Units: (A): Activity of ALP (mU/mg protein), (B): activity of LDH (μM of pyruvate liberated/min/mg protein). Values are expressed as mean ± S.D. for 6 mice in each group. aControl Vs AOM, bAOM Vs AOM+LUT, ns-non significant P<0.05
Click here to view |
Luteolin decreased the expression of iNOS
[Figure 2]a shows expression of iNOS in colon tissue. Colon tissue section from control (a) and drug control (d) mouse showed a small level of immunostaining for iNOS. AOM produced an increased expression of iNOS in colon tissues, as shown in (b). The LUT treatment reduced the AOM-induced expression of this iNOS (c). The immunohistochemical staining of iNOS was quantified and the result of the same is represented in [Figure 2]b. Similar results were observed in RT-PCR analysis of iNOS [Figure 2]c]. The imageJ analysis of PCR bands were quantified and illustrated in [Figure 2]d. | Figure 2: Luteolin decreases the expression of iNOS (a): (Control) Normal expression of iNOS, (b): (AOM) high expression of iNOS (brown color) was observed, (c): (AOM+LUT) lesser degree of expression of iNOS was noticed, (d): (LUT) Expression was similar to that of control. −> shows the expression of iNOS. (2B), Quantification of the expressions of iNOS. Values are expressed as mean ± S.D. Comparisons: aControl Vs AOM, bAOM Vs AOM+LUT, ns-non significant *P < 0.05. (2C): RT-PCR analysis of iNOS. The band was detected at the 194 bp and Actin was at 842 bp. The quantifi cation of iNOS was normalized with Actin shown in 2D
Click here to view |
Luteolin decreased the expression of COX-2
An elevated level of COX-2 has been reported in CRC and selective inhibitors of COX-2 could greatly reduce the tumor burden. Control mouse colon tissue section showed a small degree of immunostaining for COX-2 [Figure 3]a]. AOM induction increased the levels of COX-2 protein in the colon tissues, as evident from intense and wide spread brown staining in colon tissues (b). However treatment with LUT significantly reduced the expression of COX-2 (c), when compared to AOM induced group. The immunohistochemical staining of COX-2 was quantified and the result of the same is represented in [Figure 3]b. Similar results were observed in RT-PCR analysis of COX-2 [Figure 3]c]. The ImageJ software analysis of PCR bands were quantified and illustrated in [Figure 3]d. The results of this study exhibited that LUT could reduce the expressions of these inflammatory markers during CRC. | Figure 3: Luteolin decreases the expression of COX-2 (a): (Control) Normal expression of COX-2, (b): (AOM) high expression of COX-2 (brown color) was observed, (c): (AOM+LUT) lesser degree of expression of COX-2 was noticed, (d): (LUT) Expression was similar to that of control. −> indicates the expression of COX-2 protein. (3B): Quantification of the expression of COX-2. Values are expressed as mean ± S.D. Comparisons: aControl Vs AOM, bAOM Vs AOM+LUT, nsnon significant *P < 0.05. (2C): RT-PCR analysis of COX-2. The band was detected at the 247 bp and Actin was at 842 bp. The quantification of COX-2 was normalized with Actin shown in 3D
Click here to view |
| Discussion | | |
Flavonoids constitute the largest and most important group of polyphenolic compounds in plants. They are widely distributed in many frequently consumed beverages and food products of plant origin such as fruit, vegetables, wine, tea and cocoa. [22],[23] Intake of beverages or food products containing flavonoids has been frequently associated with a reduced risk for developing various cancers. [22],[24]
Several studies showed increased expression and activity of iNOS in human colon adenomas. [25],[26],[27] In the present investigation, the expression of iNOS was increased in AOM-induced mice. The expression of iNOS and nitrotyrosine accumulation (marker of peroxynitrite, the product of NO and superoxide) in inflamed mucosa of patients with ulcerative colitis and gastritis demonstrate the production of NO and its potential involvement in the pathogenesis of these diseases. [28] Studies in experimental models of CRC indicate that AOM-induced colon tumors have higher expression and/or activity of iNOS compared to levels found in adjacent colonic tissue. [29],[30] But, LUT have a strong ability to suppress iNOS and indirectly prevent the production of NO in disease conditions, [31],[32],[33] which was concordant with our present study.
The role of COX-2 as an enhancer of carcinogenesis in many organs including the colon is receiving increasing attention. Hence, assays of COX-2 expression may be used to monitor the process of carcinogenesis, and the suppression of COX-2 expression has become an important target for treatment and prevention of CRC. [34],[35],[36] COX-2 is induced by inflammatory cells, by various stimuli including cytokines, growth factors and tumor inducing factors. Overexpression of COX-2 results in dedifferentiation, adhesion to extra-cellular matrices and inhibition of programmed cell death in untransformed rat intestinal epithelial cells. [37] Inducibility of COX-2 in response to mitogenic stimuli, oncogenes and tumor promoters link it to cell proliferation. [38] Increased COX-2 expression leads to the elevated levels of PGE 2 , that is correlated with increased MDA, which forms an adduct with DNA in human colon leads to carcinogenesis [39] or inhibit apoptosis in epithelial tumor cells. [40] In the present study, the expression of COX-2 protein in colon tumors was higher than that of normal colonic mucosa. Abundant evidences supports, the role of COX-2 is involved in CRC [37],[41],[42] and provides the basis for the development of COX-2 selective inhibitors for CRC prevention and treatment. [43] Many reports stating that, LUT selectively inhibits COX-2 in various disease conditions. [33],[44] Administration of LUT directly suppresses the expression of COX-2 and thereby reduced the inflammation in colon. Recently we reported that LUT modulates the status of ATPases in AOM-induced CRC [45] and inhibits wnt/β-catenin signaling in vitro. [46]
Our own observations indicated that the LUT, potentially inhibit CRC in rodents. The results obtained from the above findings clearly indicated that, Luteolin inhibits the expression both iNOS and COX-2 in AOM-induced colon carcinogenesis. These two proteins are important mediator of inflammation associated cancer. Hence, LUT act as a novel chemotherapeutic agent to treat CRC.
| Acknowledgement | | |
We sincerely thank Council for Scientific and Industrial Research (CSIR), New Delhi, India for funding this project.
| References | | |
| 1. | Pandurangan AK. Potential targets for the prevention of colorectal cancer: A focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev 2013;14 : 2201-5. 
|
| 2. | Shike M, Winawer SJ, Greenwald PH, Bloch A, Hill MJ, Swaroop SV. Primary prevention of colorectal cancer: WHO collaborating center for prevention of colorectal cancer. Bull World Health Organ 1990;68:377-85.
|
| 3. | Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;1325:1593-6.
|
| 4. | Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
|
| 5. | Macejová D, Brtko J. Chemically induced carcinogenesis: A comparison of 1-methyl-1-nitrosourea, 7,12-dimethylbenzanthracene, diethylnitrosoamine and azoxymethane models. Endocr Regul 2001;35:53-9.
|
| 6. | Reddy BS. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen 2004;44:26-35.
|
| 7. | Corpet DE, Pierre F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemol Biomarkers Prev 2003;12:391-400.
|
| 8. | Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin 2004;54:150-80.
|
| 9. | Ashokkumar P, Sudhandiran G. Protective role of Luteolin on the status of lipid peroxidation and antioxidant defense against Azoxymethane-induced experimental colon carcinogenesis. Biomed Pharmacother 2008;62:590-7.
|
| 10. | Dall'Acqua S, Innocenti G. Antioxidant compounds from Chaerophyllum hirsutum extracts. Fitoterapia 2004;75:592-5.
|
| 11. | Pettit GR, Hoard MS, Doubek DL, Schmidt JM, Petit RK, Tackett LP, et al. Antineoplastic agents 338. The cancer cell growth inhibitory constituents of Terminalia Arjuna (Combretaceae). J Ethnopharmacol 1996;53:57-63.
|
| 12. | Post JF, Varma RS. Growth inhibitory effects of bioflavonoids and related compounds on human leukemic CEM-C1 and CEM-C7 cells. Cancer Lett 1992;24:207-13.
|
| 13. | Yin F, Giuliano AE, Van Herle AJ. Growth inhibitory effects of flavonoids in human thyroid cancer cell lines. Thyroid 1999;19:369-76.
|
| 14. | Subbaramiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56:4424-9.
|
| 15. | Huang DS, Shen KZ, Wei JF, Liang TB, Zheng SS, Xie HY. Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2. World J Gastroenterol 2005;11:204-7.
|
| 16. | Pandurangan AK, Dharmalingam P, Anandasadagopan AK, Sudhandiran G. Effect of Luteolin on the levels of glycoproteins duringAzoxymethane-induced colon carcinogenesis in mice. Asian Pac J Cancer Prev 2012;13:1569-73.
|
| 17. | Pandurangan AK, Ganapasam S. Luteolin modulates cellular thiols on azoxymethane-induced colon carcinogenesis. Asian J Exp Biol Sci 2013;4:245-50.
|
| 18. | Pandurangan AK, Ganapsam S. Luteolin induces apoptosis in azoxymethane-induced colon carcinogenesis through the involvement of Bcl-2, Bax, and Caspase-3. J Chem Pharm Res 2013;5:143-8.
|
| 19. | King J. The hydrolases-acid and alkaline phosphatases. In: Van D, editor. Practical Clinical Enzymology. London: Nostrand Co.; 1965a. p. 99-208.
|
| 20. | King J. The dehydrogenase of oxido-reductase-lactate dehydrogenase. In: Van D, editor. Practical Clinical Enzymology. London: Nostrand; 1965b. p. 83-93.
|
| 21. | Ashokkumar P, Sudhandiran G. Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/β-catenin pathway. Invest New Drugs 2011;29:273-84.
|
| 22. | Ross JA, Kasum CM. Dietary flavonoids: Bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002;22:19-34.
|
| 23. | Beecher GR. Overview of dietary flavonoids: Nomenclature, occurrence and intake. J Nutr 2003;133:3248-54.
|
| 24. | Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliovaara M, Reunanen A, et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 2002;76:560-8.
|
| 25. | Ambs S, Merriam WG, Bennett WP, Felley-Bosco E, Oqunfusika MO, Oser SM, et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: Implication for tumor angiogenesis and colon cancer progression. Cancer Res 1998;58:334-41.
|
| 26. | Lala PK, Chekraborty C. Role of nitric oxide in carcinogenesis and tumor progression. Lancet Oncol 2001;3:149-52.
|
| 27. | Cianchi F, Cortesini C, Fantappiè O, Messerini L, Schiavone N, Vannacci A, et al. Inducible nitric oxide synthase expression in human colorectal cancer: Correlation with tumor angiogenesis. Am J Pathol 2003;162:793-801.
|
| 28. | Middleton SJ, Shorthouse MJ, Hunter JO. Increased nitric oxide synthesis in ulcerative colitis. Lancet 1993;341:465-6.
|
| 29. | Takahashi M, Fukuda, K, Ohata T, Sugimura T, Wakabayashi K. Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res 1997;57:1233-7.
|
| 30. | Rao CV, Kawamori T, Hamid R, Simi B, Gambrell B, Reddy BS. Chemoprevention of aberrant crypt foci by inducible nitric oxide synthase-selective inhibitors: A safer colon cancer chemopreventive strategy. Carcinogenesis 1998;20:641-4.
|
| 31. | Comalada M, Ballester I, Bailón E, Sierra S, Xaus J, Galvez J, et al. Inhibition of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring flavonoids: Analysis of the structure-activity relationship. Biochem Pharmacol 2006;72:1010-21.
|
| 32. | Gutiérrez-Venegas G, Kawasaki-Cárdenas P, Arroyo-Cruz SR, Maldonado-Frías S. Luteolin inhibits lipopolysaccharide actions on human gingival fibroblasts. Eur J Pharmacol 2006;541:95-105.
|
| 33. | Chen CY, Peng WH, Tsai KD, Hsu SL. Luteolin suppresses inflammation associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci 2007;81:1602-14.
|
| 34. | Sharma RA, Gescher A, Plastaras JP. Cyclooxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells. Carcinogenesis 2001;22:1557-60.
|
| 35. | Tanaka T, Shimizu M, Kohno H, Yoshitani S, Tsukio Y, Murakami A, et al. Chemoprevention of azoxymethane-induced rat aberrant crypt foci by dietary zerumbone isolated from Zingiber zerumbet. Life Sci 2001;69:1935-45.
|
| 36. | Turini ME, DuBois RN. Cyclooxygenase-2: A therapeutic target. Annu Rev Med 2002;53:35-57.
|
| 37. | Tsujii M, DuBois RN. Alteration in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
|
| 38. | Singh J, Hamid R, Reddy BS. Dietary fat and colon cancer: Modulation of cyclooxygenase-2 by types and amount of dietary fat during the post initiation stage of colon carcinogenesis. Cancer Res 1997;57:3465-70.
|
| 39. | Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-45.
|
| 40. | Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6.
|
| 41. | Taketo MM. Cycloxygense-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998;90:1529-34.
|
| 42. | Rao CV, Reddy BS. NASIDs and chemoprevention. Curr Cancer Drug Targets 2004;4:29-43.
|
| 43. | Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, et al. Chemoprevention of colon cancer by specific cycloxygenase-2 inhibitor, celeoxib, administrated during different stages of carcinogenesis. Cancer Res 2000;60:293-8.
|
| 44. | Ziyan L, Yongmei Z, Nan Z, Ning T, Baolin L. Evaluation of the anti-inflammatory activity of luteolin in experimental animal models. Planta Med 2007;73:221-6.
|
| 45. | Pandurangan AK, Dharmalingam P, Anandasadagopan SK, Ganapasam S. Inhibitory effect of Luteolin on the status of membrane bound ATPases against Azoxymethane-induced colorectal cancer. J Chem Pharm Res 2013;5:123-7.
|
| 46. | Pandurangan AK, Dharmalingam P, Ananda Sadagopan SK, Ramar M, Munusamy A, Ganapasam S. Luteolin induces growth arrest in colon cancer cells via Wnt/β-catenin signaling mediated through GSK-3β. J Environ Pathol Toxicol Oncol 2013;32:10.
|
[Figure 1], [Figure 2], [Figure 3]
[Table 1]
| This article has been cited by | | 1 |
Caffeic Acid Phenethyl Ester Attenuates Dextran Sulfate Sodium-Induced Ulcerative Colitis Through Modulation of NF-?B and Cell Adhesion Molecules |
|
| Ashok Kumar Pandurangan, Nooshin Mohebali, Mohadeseh Hasanpourghadi, Norhaizan Mohd Esa | | Applied Biochemistry and Biotechnology. 2022; | | [Pubmed] | [DOI] | | | 2 |
Piperlongumine targets NF-?B and its downstream signaling pathways to suppress tumor growth and metastatic potential in experimental colon cancer |
|
| Sandeep Kumar, Navneet Agnihotri | | Molecular and Cellular Biochemistry. 2021; 476(4): 1765 | | [Pubmed] | [DOI] | | | 3 |
Formulation, characterization, and evaluation of the anti-tumor activity of nanosized galangin loaded niosomes on chemically induced hepatocellular carcinoma in rats |
|
| Shereen Sabry, Abd El hakim Ramadan, Mahmoud Abd elghany, Tarek Okda, Azza Hasan | | Journal of Drug Delivery Science and Technology. 2021; 61: 102163 | | [Pubmed] | [DOI] | | | 4 |
Luteolin alleviates inflammation and modulates gut microbiota in ulcerative colitis rats |
|
| Bolin Li, Pengli Du, Yao Du, Danyang Zhao, Yanru Cai, Qian Yang, Zijing Guo | | Life Sciences. 2021; 269: 119008 | | [Pubmed] | [DOI] | | | 5 |
Precise regulation of inflammation and immunosuppressive microenvironment for amplified photothermal/immunotherapy against tumour recurrence and metastasis |
|
| Yanbing Wang, Caina Xu, Meng Meng, Lin Lin, Yingying Hu, Kai Hao, Shu Sheng, Sijia Zhang, Jiayan Wu, Feng Liu, Xiue Jiang, Huayu Tian, Xuesi Chen | | Nano Today. 2021; 40: 101266 | | [Pubmed] | [DOI] | | | 6 |
The Hallmarks of Flavonoids in Cancer |
|
| Luis Gustavo Saboia Ponte, Isadora Carolina Betim Pavan, Mariana Camargo Silva Mancini, Luiz Guilherme Salvino da Silva, Ana Paula Morelli, Matheus Brandemarte Severino, Rosangela Maria Neves Bezerra, Fernando Moreira Simabuco | | Molecules. 2021; 26(7): 2029 | | [Pubmed] | [DOI] | | | 7 |
Design and Optimization of Orally Administered Luteolin Nanoethosomes to Enhance Its Anti-Tumor Activity against Hepatocellular Carcinoma |
|
| Mahmoud M. A. Elsayed, Tarek M. Okda, Gamal M. K. Atwa, Gamal A. Omran, Atef E. Abd Elbaky, Abd El hakim Ramadan | | Pharmaceutics. 2021; 13(5): 648 | | [Pubmed] | [DOI] | | | 8 |
Phytochemical Screening of Himatanthus sucuuba (Spruce) Woodson (Apocynaceae) Latex, In Vitro Cytotoxicity and Incision Wound Repair in Mice |
|
| Oscar Herrera-Calderón, Lisbeth Lucia Calero-Armijos, Wilson Cardona-G, Angie Herrera-R, Gustavo Moreno, Majed A. Algarni, Mohammed Alqarni, Gaber El-Saber Batiha | | Plants. 2021; 10(10): 2197 | | [Pubmed] | [DOI] | | | 9 |
Chemoprotective Effects of Geraniin against Azoxymethane Induced Colorectal Cancer by Reduction of Inflammatory Reaction |
|
| Ruize Zhou, Jia Lei, Yubo Wei, Hongbin Zhang | | Journal of Oleo Science. 2021; 70(6): 817 | | [Pubmed] | [DOI] | | | 10 |
Differential relieving effects of shikonin and its derivatives on inflammation and mucosal barrier damage caused by ulcerative colitis |
|
| Hongwei Han, Wenxue Sun, Lu Feng, Zhongling Wen, Minkai Yang, Yingying Ma, Jiangyan Fu, Xiaopeng Ma, Xinhong Xu, Zhaoyue Wang, Tongming Yin, Xiao-Ming Wang, Gui-Hua Lu, Jin-Liang Qi, Hongyan Lin, Yonghua Yang | | PeerJ. 2021; 9: e10675 | | [Pubmed] | [DOI] | | | 11 |
Protective effect of Matricaria chamomilla extract against 1,2-dimethylhydrazine-induced colorectal cancer in mice |
|
| Manal M. El Joumaa, Robin I. Taleb, Sandra Rizk, Jamilah M. Borjac | | Journal of Complementary and Integrative Medicine. 2020; 17(3) | | [Pubmed] | [DOI] | | | 12 |
Anti-inflammatory Activity of Mollugin on DSS-induced Colitis in Mice |
|
| Juan Li, Jin-ling Zhang, Xue-peng Gong, Meng Xiao, Yuan-yuan Song, Hui-fang Pi, Guang Du | | Current Medical Science. 2020; 40(5): 910 | | [Pubmed] | [DOI] | | | 13 |
Luteolin, a flavonoid, as an anticancer agent: A review |
|
| Muhammad Imran, Abdur Rauf, Tareq Abu-Izneid, Muhammad Nadeem, Mohammad Ali Shariati, Imtiaz Ali Khan, Ali Imran, Ilkay Erdogan Orhan, Muhammad Rizwan, Muhammad Atif, Tanweer Aslam Gondal, Mohammad S. Mubarak | | Biomedicine & Pharmacotherapy. 2019; 112: 108612 | | [Pubmed] | [DOI] | | | 14 |
Luteolin inhibits colorectal cancer cell epithelial-to-mesenchymal transition by suppressing CREB1 expression revealed by comparative proteomics study |
|
| Yuan Liu,Tingyuan Lang,Bingwei Jin,Feng Chen,Yi Zhang,Roger W. Beuerman,Lei Zhou,Zhiqi Zhang | | Journal of Proteomics. 2017; | | [Pubmed] | [DOI] | | | 15 |
Luteolin suppresses the JAK/STAT pathway in a cellular model of intestinal inflammation |
|
| Carla Nunes,Leonor Almeida,Rui M. Barbosa,João Laranjinha | | Food Funct.. 2017; 8(1): 387 | | [Pubmed] | [DOI] | | | 16 |
Molecular mechanisms of flavonoids in melanin synthesis and the potential for the prevention and treatment of melanoma |
|
| Feng Liu-Smith,Frank L. Meyskens | | Molecular Nutrition & Food Research. 2016; 60(6): 1264 | | [Pubmed] | [DOI] | | | 17 |
Harmal Extract Induces Apoptosis of HCT116 Human Colon Cancer Cells, Mediated by Inhibition of Nuclear Factor-?B and Activator Protein-1 Signaling Pathways and Induction of Cytoprotective Genes |
|
| Ayman I Elkady,Rania A Hussein,Sufian M El-Assouli | | Asian Pacific Journal of Cancer Prevention. 2016; 17(4): 1947 | | [Pubmed] | [DOI] | | | 18 |
An insight into the role of citrus bioactives in modulation of colon cancer |
|
| Jasleen Kaur,Gurpreet Kaur | | Journal of Functional Foods. 2015; 13: 239 | | [Pubmed] | [DOI] | | | 19 |
Dietary cocoa inhibits colitis associated cancer: a crucial involvement of the IL-6/STAT3 pathway |
|
| Zeinab Saadatdoust,Ashok Kumar Pandurangan,Suresh Kumar Ananda Sadagopan,Norhaizan Mohd. Esa,Amin Ismail,Mohd. Rais Mustafa | | The Journal of Nutritional Biochemistry. 2015; 26(12): 1547 | | [Pubmed] | [DOI] | | | 20 |
Gallic acid suppresses inflammation in dextran sodium sulfate-induced colitis in mice: Possible mechanisms |
|
| Ashok Kumar Pandurangan,Nooshin Mohebali,Norhaizan Mohd. Esa,Chung Yeng Looi,Salmiah Ismail,Zeinab Saadatdoust | | International Immunopharmacology. 2015; 28(2): 1034 | | [Pubmed] | [DOI] | | | 21 |
Vitamin D3 enhances the tumouricidal effects of 5-Fluorouracil through multipathway mechanisms in azoxymethane rat model of colon cancer |
|
| Bassem Refaat,Adel Galal El-Shemi,Osama Adnan Kensara,Amr Mohamed Mohamed,Shakir Idris,Jawwad Ahmad,Athar Khojah | | Journal of Experimental & Clinical Cancer Research. 2015; 34(1) | | [Pubmed] | [DOI] | | | 22 |
Growth inhibition of luteolin on HepG2 cells is induced via p53 and Fas/Fas-ligand besides the TGF-ß pathway |
|
| Su Yee,Hye Choi,Sang Chung,Dong Park,Bokyung Sung,Hae Chung,Nam Kim | | International Journal of Oncology. 2015; | | [Pubmed] | [DOI] | | | 23 |
Luteolin, a Bioflavonoid Inhibits Colorectal Cancer through Modulation of Multiple Signaling Pathways: A Review |
|
| Ashok Kumar Pandurangan,Norhaizan Mohd Esa | | Asian Pacific Journal of Cancer Prevention. 2014; 15(14): 5501 | | [Pubmed] | [DOI] | |
|
 |
|
|
|
